Platinum-polymer complexes and their use as antitumor agents
First Claim
1. A polymeric platinum-amine complex of the formula ##STR9## wherein each A independently represents a monodentate amine ligand or NH3 or A2 represents a single bidentate amine ligand;
- n is a positive integer up to 500;
P is a divalent ligand of a physiologically acceptable homopolymer or copolymer bearing at least 2×
n pendant anionic groups, pairs of which form covalent linkages with the Pt(II)A2 or Pt(IV)A2 group; and
X is an anionic ligand.
3 Assignments
0 Petitions
Accused Products
Abstract
Platinum(amine) complexes, when covalently linked to a water-soluble, biodegradable or biostable polymer, exhibit high antitumor activity at low dosages of platinum against L1210 and solid tumors. The complexes are platinum square planar complexes and octahedral structures of the formulae ##STR1## wherein A2 represents either 2 ammonia ligands, 2 monodentate amine ligands or a single bidentate amine ligand; P is either a biodegradable or a biostable but biocompatible polymer having pendent anionic groups which form covalent linkages with Pt; o is a positive integer and X is an anionic ligand.
-
Citations
26 Claims
-
1. A polymeric platinum-amine complex of the formula ##STR9## wherein each A independently represents a monodentate amine ligand or NH3 or A2 represents a single bidentate amine ligand;
-
n is a positive integer up to 500; P is a divalent ligand of a physiologically acceptable homopolymer or copolymer bearing at least 2×
n pendant anionic groups, pairs of which form covalent linkages with the Pt(II)A2 or Pt(IV)A2 group; andX is an anionic ligand. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 19, 20, 21, 22, 23, 24, 25, 26)
-
-
17. A method of treating a patient with a tumor susceptible to platinum therapy by administering thereto a platinum-amine complex which exhibits anti-tumor activity against L1210 tumors and solid tumors, which comprises administering the platinum-amine complex to the affected host as a conjugate with a water-soluble, physiologically acceptable anionic polymer, thereby reducing the amount of the complex required to be administered thereto to manifest the anti-tumor activity thereof in the patient.
Specification